EGFR and head and neck squamous cell carcinoma: Targeting EGFR with either an antibody (e.g., cetuximab) or small molecule inhibitor (e.g., erlotinib) has been extensively investigated in clinical trials and has been approved by the Food and Drug Administration (FDA) for the treatment of patients with primary or R/M HNSCC [2, 11, 14, 15, 16].